Homogeneous Immunoassays—Therapeutic Drug Monitoring
Innofluor®—Fluorescence Polarization Immunoassays To view and print the files below you will need Adobe Acrobat Reader®,
which is available for free from Adobe's website.
INNOFLUOR® Theophylline Assay System
The INNOFLUOR® THEOPHYLLINE Assay System is intended for the quantitative determination of total theophylline in serum for therapeutic drug monitoring by fluorescence polarization immunoassay (FPIA). The assay system is for use on the TDx® or the TDxFlxTM (TDx®/TDxFLx®) analyzer.
Theophylline is a methylxanthine used to treat bronchospasm, including asthma, and obstructive airway disease.1,2 Its effectiveness as a bronchodilator agent overrides the low margin of safety between its effective therapeutic level and the onset of toxicity symptoms.1
Theophylline is completely and rapidly absorbed from the gastro-intestinal tract, with an oral dose being absorbed in one hour and peak plasma concentrations being achieved in two hours.3-5 The drug is widely distributed in body fluids. In plasma about forty percent is protein bound.6 Theophylline is eliminated from the body via several parallel pathways. Approximately ten percent is eliminated unchanged by the kidneys, while the remainder is metabolized, apparently in the liver, largely to uric acid derivatives and 3-methylxanthine.2,6-8
Theophylline has a narrow therapeutic index with a range for serum levels from 10-20ug/ml.6,9,10 Individualized dosing and routine serum level monitoring are necessary for patients receiving theophylline, due to wide variation in theophylline absorption, metabolism and clearance.6,9,10
Weinberger M, Hendeles L, Johnson G. Rationale of procedures for monitoring serum theophylline levels. In: Baer DM ed. Technical Improvement Service, American Society of Clinical Pathologists. Chicago, 1978;3.
Bierman CW, Williams, PV. Therapeutic monitoring of theophylline. Rationale and current status. Clin Pharmacokinet 1989; 17(6): 377-384.
Hendeles L, Weinberer M, Bighley L. Disposition of theophylline following a single intravenous aminophylline infusion. Am Rev Respir Dis 1978; 118: 97-103.
Aranda JV, et al. Pharmacokinetic aspects of theophylline in premature newborns. N Eng J Med 1976; 295: 413-416.
Rowe DJ, Watson ID, Williams J, Berry DJ. The clinical use and measurement of theophylline. Ann Clin Biochem 1988; 25: 4-26.
Levy G, Koysooko R. Renal clearance of theophylline in man. J Clin Pharmacol 1976; 16: 329-332.
Jenne JW, Wyze E, Rood FS, MacDonald RM. Pharmacokinetics of theophylline: application to adjustment of the clinical dose of aminophylline. Clin Pharmacol Ther 1972; 13: 349-360.
Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. American Journal of Medicine 1990; 88(6): 567-576.
